<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03046108</url>
  </required_header>
  <id_info>
    <org_study_id>0565-N-16</org_study_id>
    <nct_id>NCT03046108</nct_id>
  </id_info>
  <brief_title>Blind and Ultrasound Guided Injection in Morton Neuroma</brief_title>
  <official_title>Comparison Between Blind and Ultrasound Guided Injection in Morton Neuroma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Complejo Hospitalario Universitario de Granada</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Complejo Hospitalario Universitario de Granada</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this work trial is to compare the effectiveness of blind and ultrasound guided
      injection for Morton neuroma in order to determine which is more appropriate as the initial
      procedure in conservative treatment
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a evaluator-blinded randomized trial. The final sample size has been calculated to be
      100 patients. 50 of group 1 are going to be injected by an experimented orthopaedic surgeon
      based on anatomic landmark. 50 of group 2 are going to be injected by an experimented
      musculoskeletal radiologist under ultrasound guidance.

      The inclusion criteria are clinical suspicion of Morton neuroma confirmed in ultrasound scan.
      Included patients are assessed clinically by VAS score, the Manchester Foot Pain and
      Disability Schedule (MFPDS), and a generic quality-of-life instrument, the EQ-5D.

      Injection includes 1 cc of 2% mepivacaine and 40 mg of triamcinolone in each web space with
      Morton Neuroma. According evolution until 4 injections were allowed the first 2 months of
      follow-up, Follow up was performed by phone calls and/or scheduled consultations at 15 days,
      1 month, 45 days, 2 months, 3 months, 6 months and 1 year.

      Statistical analysis was performed by unpaired Student's t test
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain (VAS score)</measure>
    <time_frame>1 year</time_frame>
    <description>Pain relieve</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Manchester foot pain and disability index</measure>
    <time_frame>1 year</time_frame>
    <description>Disability measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Generic quality-of-life instrument, the EQ-5D</measure>
    <time_frame>1 year</time_frame>
    <description>Quality of life measurement</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Morton Neuroma</condition>
  <arm_group>
    <arm_group_label>blind injection of Morton neuroma</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Percoutaneous blind injection in Morton neuroma by subcutaneous needle group 1 are going to be injected by an experimented orthopaedic surgeon based on anatomic landmark. There is no internal control of the needle placement.
Mixture of 1 cc of 2% mepivacaine (Mepivacaina Normon 2%® )+ 40 mg of triamcinolone (Trigon Depot®) in each of the web spaces affected with Morton neuroma is injected.
Up to 4 injections are allow in the first three months of follow-up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>blind injection of Mepivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 cc of 2% mepivacaine (Mepivacaina Normon 2%® )+ 40 mg of triamcinolone (Trigon Depot®) in each of the web spaces affected with Morton neuroma is injected.
Up to 4 injections are allow in the first three months of follow-up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>blind injection of Triamcinolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>40 mg of triamcinolone (Trigon Depot®) in each of the web spaces affected with Morton neuroma is injected. Up to 4 injections are allow in the first three months of follow-up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ultrasound guided injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>US guided injection in Morton neuroma by subcutaneous needle. group 2 are going to be injected by an experimented musculoskeletal radiologist under ultrasound guidance. There is internal control of needle placement by ultrasound.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>guided injection of mepivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2% mepivacaine (Mepivacaina Normon 2%® ) in each of the web spaces affected with Morton neuroma is injected.
Up to 4 injections are allow in the first three months of follow-up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>guided injection of Triamcinolone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 mg of triamcinolone (Trigon Depot®) in each of the web spaces affected with Morton neuroma is injected. Up to 4 injections are allow in the first three months of follow-up</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>blind injection of Morton neuroma</intervention_name>
    <description>Introduction of a needle based in anatomical landmark</description>
    <arm_group_label>blind injection of Morton neuroma</arm_group_label>
    <arm_group_label>blind injection of Mepivacaine</arm_group_label>
    <arm_group_label>blind injection of Triamcinolone</arm_group_label>
    <other_name>Blind introduction of the needle</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>blind injection of Mepivacaine</intervention_name>
    <description>blind injection of 1 cc of Mepivacaine Normon 2% ®</description>
    <arm_group_label>blind injection of Morton neuroma</arm_group_label>
    <arm_group_label>blind injection of Mepivacaine</arm_group_label>
    <arm_group_label>blind injection of Triamcinolone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>blind injection of Triamcinolone</intervention_name>
    <description>blind injection of 40 mg of triamcinolone (trigon depot ®)</description>
    <arm_group_label>blind injection of Morton neuroma</arm_group_label>
    <arm_group_label>blind injection of Mepivacaine</arm_group_label>
    <arm_group_label>blind injection of Triamcinolone</arm_group_label>
    <other_name>Blind introduction of Triamcinolone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ultrasound guided injection</intervention_name>
    <description>Introduction of a needle based guided by ultrasound</description>
    <arm_group_label>ultrasound guided injection</arm_group_label>
    <arm_group_label>guided injection of mepivacaine</arm_group_label>
    <arm_group_label>guided injection of Triamcinolone</arm_group_label>
    <other_name>guided introduction of the needle</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>guided injection of mepivacaine</intervention_name>
    <description>ultrasound guided injection of 1 cc of Mepivacaine Normon 2% ®</description>
    <arm_group_label>ultrasound guided injection</arm_group_label>
    <arm_group_label>guided injection of mepivacaine</arm_group_label>
    <arm_group_label>guided injection of Triamcinolone</arm_group_label>
    <other_name>guided perineural injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>guided injection of Triamcinolone</intervention_name>
    <description>ultrasound guided injection of 40 mg of triamcinolone (trigon depot ®)</description>
    <arm_group_label>ultrasound guided injection</arm_group_label>
    <arm_group_label>guided injection of mepivacaine</arm_group_label>
    <arm_group_label>guided injection of Triamcinolone</arm_group_label>
    <other_name>guided perineural injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical suspicion of Morton neuroma confirmed in ultrasound scan

          -  Symptoms present more than six months

          -  The thickness of the nerve must be at least 2 mm in short axis and at least 5 mm in
             the longitudinal axis.

        Exclusion Criteria:

          -  Contraindication for the use of corticosteroids or local anesthetics

          -  Presence of inflammatory arthropathy or neuropathy

          -  Skin lesions in the area

          -  diabetes mellitus

          -  Infiltration or previous surgery in the area

          -  Refusal to participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>FERNANDO RUIZ SANTIAGO, PhD</last_name>
    <role>Study Director</role>
    <affiliation>COMPLEJO HOSPITALARIO UNIVERSITARIO GRANADA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>PABLO TOMAS MUÑOZ, PhD</last_name>
    <phone>+34617516708</phone>
    <email>pablotomasm@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>ANA MARIA DEL VALLE DIAZ DE LA GUARDIA, MD</last_name>
    <phone>+34958895414</phone>
    <email>anam.valle.sspa@juntadeandalucia.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario Granada</name>
      <address>
        <city>Granada</city>
        <state>SPA</state>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JUANA MARIA DE HARO CASTELLANO</last_name>
      <phone>+34958 020124</phone>
      <email>juanam.haro.exts@juntadeandalucia.es</email>
    </contact>
    <contact_backup>
      <last_name>JUAN MORALES ARCAS</last_name>
      <phone>+34 958 023136</phone>
      <email>juan.morales.sspa@juntadeandalucia.es</email>
    </contact_backup>
    <investigator>
      <last_name>NICOLAS PRADOS OLLETA, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>PABLO TOMAS MUÑOZ</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <results_reference>
    <citation>Saygi B, Yildirim Y, Saygi EK, Kara H, Esemenli T. Morton neuroma: comparative results of two conservative methods. Foot Ankle Int. 2005 Jul;26(7):556-9.</citation>
    <PMID>16045848</PMID>
  </results_reference>
  <results_reference>
    <citation>Thomson CE, Beggs I, Martin DJ, McMillan D, Edwards RT, Russell D, Yeo ST, Russell IT, Gibson JN. Methylprednisolone injections for the treatment of Morton neuroma: a patient-blinded randomized trial. J Bone Joint Surg Am. 2013 May 1;95(9):790-8, S1. doi: 10.2106/JBJS.I.01780.</citation>
    <PMID>23636185</PMID>
  </results_reference>
  <results_reference>
    <citation>Mahadevan D, Attwal M, Bhatt R, Bhatia M. Corticosteroid injection for Morton's neuroma with or without ultrasound guidance: a randomised controlled trial. Bone Joint J. 2016 Apr;98-B(4):498-503. doi: 10.1302/0301-620X.98B4.36880.</citation>
    <PMID>27037432</PMID>
  </results_reference>
  <results_reference>
    <citation>Hassouna H, Singh D, Taylor H, Johnson S. Ultrasound guided steroid injection in the treatment of interdigital neuralgia. Acta Orthop Belg. 2007 Apr;73(2):224-9.</citation>
    <PMID>17515235</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2016</study_first_submitted>
  <study_first_submitted_qc>February 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2017</study_first_posted>
  <last_update_submitted>October 17, 2017</last_update_submitted>
  <last_update_submitted_qc>October 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Complejo Hospitalario Universitario de Granada</investigator_affiliation>
    <investigator_full_name>FERNANDO RUIZ SANTIAGO</investigator_full_name>
    <investigator_title>PhD, section chief musculoskeletal radiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroma</mesh_term>
    <mesh_term>Morton Neuroma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
    <mesh_term>Mepivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>our idea is to publish the short term results and the long term results in order to influence management of this pathology. Tables and statistical analysis will be available for review and metaanalysis.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

